Treatment with Tigecycline of Recurrent Urosepsis Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli
- 1 February 2008
- journal article
- case report
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (2), 817-820
- https://doi.org/10.1128/jcm.01340-07
Abstract
A 25-year-old female was admitted to our intensive care unit with septic shock and multiorgan failure caused by extended-spectrum β-lactamase-producing Escherichia coli originating from the right renal pelvis. A 16-day course of treatment with meropenem reversed the septic condition, but the infection recurred thereafter. The patient recovered fully after therapy was changed to tigecycline.Keywords
This publication has 7 references indexed in Scilit:
- Continuous infusion of β-lactam antibiotics in severe infections: a review of its roleInternational Journal of Antimicrobial Agents, 2007
- The Pharmacokinetic and Pharmacodynamic Profile of TigecyclineClinical Infectious Diseases, 2005
- Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2005
- Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shockIntensive Care Medicine, 2004
- Correlation of Meropenem Plasma Levels with Pharmacodynamic Requirements in Critically Ill Patients Receiving Continuous Veno-Venous HemofiltrationChemotherapy, 2003
- Correlation between candiduria and departmental antibiotic useJournal of Hospital Infection, 2003
- Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous HemodiafiltrationAntimicrobial Agents and Chemotherapy, 1998